This trial is not actively recruiting.

This trial has completed recruitment on this platform, and is no longer accepting new referrals.

A Phase 3 Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients with Hereditary Angioedema (HAE)

Trial ID: Oasis-HAE Study
The OASIS-HAE study is a clinical research study evaluating the safety and efficacy of donidalorsen, an investigational study drug for the potential treatment of hereditary angioedema (HAE). The OASIS-HAE study is being conducted to help address the need for new therapies for HAE.

Trial Details

The OASIS-HAE study is a phase 3 clinical trial evaluating the safety and efficacy of donidalorsen, an investigational drug, being studied for the prevention of HAE attacks. The OASIS-HAE study is being conducted to help address the need for new therapies for HAE.

OASIS-HAE will enroll 84 participants and will take place in several countries, including countries in North American and Europe.

Estimated Enrollment

84 Participants

Phase

3

Eligibility Criteria

Participants must:

  • Be 12 years or older
  • Have been diagnosed with HAE
  • Have access to and the ability to use 1 or more acute medications to treat HAE attacks

Participants must not:

  • Be younger than 12 years old

Site List

Sites are located in the cities/states identified with the red pin:

Frequently Asked Questions (FAQs)